ZOSTAVAX PACKAGE INSERT PDF

CDC recommends that healthy adults 50 years and older get two doses of Shingrix, 2 to 6 months apart. Shingrix provides strong protection against shingles and PHN. Shingrix is the preferred vaccine, over Zostavax. People with chronic medical conditions may be vaccinated unless a contraindication or precaution exists for their condition.

Author:Faeramar Kagarr
Country:Iraq
Language:English (Spanish)
Genre:Relationship
Published (Last):4 October 2004
Pages:342
PDF File Size:12.23 Mb
ePub File Size:7.79 Mb
ISBN:219-5-92164-366-2
Downloads:8204
Price:Free* [*Free Regsitration Required]
Uploader:Aralabar



CDC recommends that healthy adults 50 years and older get two doses of Shingrix, 2 to 6 months apart. Shingrix provides strong protection against shingles and PHN. Shingrix is the preferred vaccine, over Zostavax. People with chronic medical conditions may be vaccinated unless a contraindication or precaution exists for their condition.

Zostavax is a live virus vaccine. It can be administered concurrently with all other live and inactivated vaccines, including those routinely recommended for people 60 years old and older, such as influenza and pneumococcal vaccines. When vaccinating people 60 years old or older, there is no need to screen for a history of varicella chickenpox infection or to conduct laboratory testing for serologic evidence of prior varicella infection.

Even if a person reports that they have not had varicella, they can still receive the herpes zoster vaccine. If serologic evidence of varicella susceptibility becomes available to the healthcare provider, the patient should be offered varicella vaccine not herpes zoster vaccine.

Herpes zoster vaccine should be given regardless of a history of herpes zoster. Herpes zoster does recur, and there is no biological or epidemiological evidence to indicate that persons are at reduced risk for herpes zoster for any period of time following a prior occurrence of the disease.

There are no recognized safety concerns in giving the vaccine to people with prior history of herpes zoster. The general guideline for any vaccine is to wait until the acute stage of the illness is over and symptoms abate. However, CDC does not recommend routine use of this vaccine in people age 50 through 59 years.

Healthcare providers considering the herpes zoster vaccine for certain persons in age ranges should discuss the risks and benefits of vaccination with their patients. Although the vaccine has short-term efficacy, there have been no long-term studies of vaccine protection in this age group.

In adults vaccinated at age 60 years or older, vaccine efficacy wanes within the first 5 years after vaccination, and protection beyond 5 years is uncertain; therefore, adults receiving the vaccine before age 60 years might not be protected when their risks for herpes zoster and its complications are highest.

Also, healthcare providers may want to first consider whether the patients 50 to 59 years old would have poor tolerance to herpes zoster or postherpetic neuralgia symptoms. For example, if the patient has preexisting chronic pain, severe depression, or other co-morbidities, intolerance to treatment medications due to hypersensitivity or interactions with other medications, or extenuating employment-related factors. No data are available about the effectiveness of herpes zoster vaccine in adults who become immunosuppressed after their vaccination.

Contraindications and Precautions for Shingles Vaccination Zostavax should not be administered to: A person who has ever had a life-threatening or severe allergic reaction to gelatin, the antibiotic neomycin, or any other component of herpes zoster vaccine.

Women who are or might be pregnant. Women should not become pregnant until at least 4 weeks after getting herpes zoster vaccine. Someone with a minor acute illness, such as a cold, may be vaccinated. But anyone with a moderate or severe acute illness should usually wait until they recover before getting the vaccine.

This includes anyone with a temperature of

FROM ELFLAND TO POUGHKEEPSIE PDF

About the Vaccine

VZV was not detected in any of these specimens. Post-Marketing Experience The following additional adverse reactions have been identified during post-marketing use of Zostavax. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to the vaccine. Skin and subcutaneous tissue disorders: rash Musculoskeletal and connective tissue disorders: arthralgia; myalgia General disorders and administration site conditions: injection-site rash; injection-site urticaria; pyrexia; transient injection-site lymphadenopathy Hypersensitivity: hypersensitivity reactions including anaphylactic reactions Reporting Adverse Events The U. For information or a copy of the vaccine reporting form, call the VAERS toll-free number at or report online to www. For concomitant administration of Zostavax with trivalent inactivated influenza vaccine, [see Clinical Studies 14 ].

BRUNO BETTELHEIM EL PSICOANLISIS DE LOS CUENTOS DE HADAS PDF

Zostavax (Zoster Vaccine Live) Recommendations

.

HTTP WWW VODAFONE DE INFOFAXE 265 PDF

.

FREEHAND EXPORTAR PDF

.

Related Articles